ClinicalTrials.gg
CompletedNCT01313494ACROSSUpdated Feb 1, 2017Results posted

A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:

A Phase 3 interventional study of Roflumilast and Placebo in COPD, sponsored by AstraZeneca. Completed at 15 sites in 3 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-02-01.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
626
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
12th of 32
626 · median 154
Started
2011
with 4 others
Phase 3
16 of 32
none open now
Registered
12th of 32
by date
Lead sponsor
18 of 32
AstraZeneca

Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 12th largest by enrollment, is one of 5 that started in 2011, is one of 16 in phase 3, and was the 12th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The aim of this trial is to determine the efficacy, safety and tolerability of 500 µg Roflumilast tablets once daily in patients with COPD in China, Hong Kong, and Singapore.

03

Conditions studied

  • COPD

Keywords

  • COPD
  • Roflumilast
  • FEV1
  • China
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Willingness to sign a written
  • (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2009
  • Chinese or Malay or Indian ethnicity
  • History of chronic obstructive pulmonary disease symptoms for at least 12 months prior to baseline visit V0
  • / Forced vital capacity (FEV1/FVC) ratio (post-bronchodilator) \< 70%
  • Forced expiratory volume in the first second (FEV1) (post-bronchodilator) \< 50 % of predicted
  • Former smoker (defined as: smoking cessation at least one year ago) or current smoker both with a smoking history of at least 10 pack years

Main Exclusion Criteria:

  • Moderate or severe COPD exacerbation and/or COPD exacerbations treated with antibiotics not stopped at V0
  • Lower respiratory tract infection not resolved 4 weeks prior to the baseline visit V0
  • History of asthma diagnosis in patients \< 40 years of age or relevant lung disease other than COPD
  • Current participation in a pulmonary rehabilitation program or completion of a pulmonary rehabilitation program within 3 months preceding the baseline visit V0
  • Known alpha-1-antitrypsin deficiency
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
626 participants (actual)

Study arms

  • Experimental
    Roflumilast

    Roflumilast 500 μg, tablet, oral, once daily for up to 24 weeks.

    Drug: Roflumilast · Drug: Salbutamol

  • Placebo comparator
    Placebo

    Placebo to roflumilast, tablet, oral, once daily for up to 24 weeks.

    Drug: Placebo · Drug: Salbutamol

Interventions

  • Roflumilast tablets

  • DrugPlacebo

    Placebo tablets

  • Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)

    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of pre-bronchodilator FEV1, time and a treatment-by-time interaction as independent variables.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Change From Baseline in Post-bronchodilator FEV1

    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of post-bronchodilator FEV1, time and a treatment-by-time interaction as independent variables.

    Time frame: Baseline to Week 24

  2. Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC)

    Vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

    Time frame: Baseline to Week 24

  3. Change From Baseline in Post-bronchodilator Forced Vital Capacity (FVC)

    Vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

    Time frame: Baseline to Week 24

  4. Change From Baseline in Pre-bronchodilator Forced Expiratory Flow 25-75%

    Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

    Time frame: Baseline to Week 24

  5. Change From Baseline in Post-bronchodilator Forced Expiratory Flow 25-75%

    Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

    Time frame: Baseline to Week 24

  6. Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3)

    FEV3 is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of pre-bronchodilator FEV3, time and a treatment-by-time interaction as independent variables.

    Time frame: Baseline to Week 24

  7. Change From Baseline in Post-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3)

    FEV3 is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of post-bronchodilator FEV3, time and a treatment-by-time interaction as independent variables.

    Time frame: Baseline to Week 24

  8. Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6)

    FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first six seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of pre-bronchodilator FEV6, time and a treatment-by-time interaction as independent variables.

    Time frame: Baseline to Week 24

  9. Change From Baseline in Post-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6)

    FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of post-bronchodilator FEV6, time and a treatment-by-time interaction as independent variables.

    Time frame: Baseline to Week 24

  10. Change From Baseline in Pre-bronchodilator Peak Expiratory Flow Rate (PEF)

    PEF is the maximal flow (or speed) achieved during the maximally forced expiration initiated at full inspiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

    Time frame: Baseline to Week 24

  11. Change From Baseline in Post-bronchodilator Peak Expiratory Flow Rate (PEF)

    PEF is the maximal flow (or speed) achieved during the maximally forced expiration initiated at full inspiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

    Time frame: Baseline to Week 24

  12. Change From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity

    The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication.

    Time frame: Baseline and Week 24

  13. Change From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity

    The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol.

    Time frame: Baseline and Week 24

  14. Change From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds

    The FEV1/FEV6 ratio represents the percentage of the volume of air expired in the first six seconds that is expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication.

    Time frame: Baseline and Week 24

  15. Change From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds

    The FEV1/FEV6 ratio represents the percentage of the volume of air expired in the first six seconds that is expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol.

    Time frame: Baseline and Week 24

  16. Change From Baseline in COPD Symptom Scores

    Symptoms of chronic bronchitis with respect to cough and sputum production were assessed daily by the patient and recorded in a diary. Symptoms were assessed on a 4-point scale as follows: Cough: 0: no cough; 1: mild cough (at some time during the day); 2: moderate cough (regularly during the day); 3: severe cough (never free of cough or feeling free of need to cough). Sputum production: 0: no sputum production (unnoticeable); 1: mild sputum production (noticeable as a problem); 2: moderate sputum production (frequent inconvenience); 3: severe sputum production (constant problem). Change from Baseline is reported for cough and sputum separately, and for the sum of the 2 scores (range 0 - 6). Least squares means (LSM) are from a repeated measures ANCOVA model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

    Time frame: Baseline to Week 24

  17. Change From Baseline in Use of Rescue Medication

    Salbutamol (given by metered dose inhaler and spacer) was used as rescue medication according to the individual needs of a patient. Each use was documented in the patient's paper diary. Least squares means (LSM) are from a repeated measures ANCOVA model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

    Time frame: Baseline to Week 24

  18. Transition Dyspnoea Index (TDI) Total Score at Week 24

    The TDI is a recognized questionnaire to measure dyspnoea (shortness of breath) in patients with COPD. Questions from the TDI were used to assess the 3 components: "change in functional impairment", "change in magnitude of task" and "change in magnitude of effort". Transitions or changes from baseline are rated from -3 (major deterioration) to +3 (major improvement), and summed to give a total score ranging from -9 to +9. Least squares means (LSM) are from a repeated measures ANCOVA model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

    Time frame: Baseline to Week 24

  19. Percentage of Participants With Moderate or Severe COPD Exacerbations

    A COPD exacerbation is an event characterised by a worsening in the patient's baseline dyspnoea, or cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management, and may be accompanied by increased wheeze, chest tightness, purulent sputum and symptoms of cold and/or fatigue. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

    Time frame: 24 weeks

  20. Mean Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year

    The mean rate of COPD exacerbations per patient per year rate = (number of exacerbations per treatment group/time to study withdrawal per treatment group) \* 365. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

    Time frame: 24 weeks

  21. Time to Onset of First Moderate or Severe COPD Exacerbation

    Time to onset of a COPD exacerbation is defined as onset date of COPD exacerbation - date of first intake of study drug + 1 day. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

    Time frame: 24 weeks

  22. Time to Onset of Second Moderate or Severe COPD Exacerbation

    Time to onset of a COPD exacerbation is defined as onset date of COPD exacerbation - date of first intake of study drug + 1 day. At least 10 days between the stop date of an exacerbation and the start date of the following exacerbation was required for these to be be considered as two separate COPD exacerbations. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

    Time frame: 24 weeks

  23. Number of Participants With Adverse Events

    An adverse event (AE) is any untoward medical occurrence in a clinical trial participant regardless of causal relationship to study drug and regardless whether study drug has been administered. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A non-serious AE is any AE that does not meet the criteria above. Each AE was assessed by the Investigator as either 'related' or 'not related' to study drug.

    Time frame: 24 weeks

07

Results

Posted Aug 2, 2013

Participant flow

Participants took part in the study at 43 investigative sites in mainland China, Hong Kong and Singapore from 04 Mar 2011 to 16 May 2012.

Participant flow — Overall Study
MilestoneRoflumilastPlacebo
Started313313
Safety set315311
Completed246263
Not completed6750

Outcome measures

PrimaryChange From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)

FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of pre-bronchodilator FEV1, time and a treatment-by-time interaction as independent variables.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · liters
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)
litersRoflumilastPlacebo
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)0.049 ± 0.009-0.022 ± 0.009
Statistical analysis
  • Roflumilast vs Placebo · Repeated measures ANCOVA · p = <0.0001 · Lsm difference: 0.071 · 95% CI 0.046 to 0.095Independent variables: treatment, baseline value of pre-bronchodilator FEV1, time and a treatment-by-time interaction.
SecondaryChange From Baseline in Post-bronchodilator FEV1

FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of post-bronchodilator FEV1, time and a treatment-by-time interaction as independent variables.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · liters
Change From Baseline in Post-bronchodilator FEV1
litersRoflumilastPlacebo
Change From Baseline in Post-bronchodilator FEV10.045 ± 0.009-0.023 ± 0.009
SecondaryChange From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC)

Vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · liters
Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC)
litersRoflumilastPlacebo
Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC)0.100 ± 0.017-0.009 ± 0.017
SecondaryChange From Baseline in Post-bronchodilator Forced Vital Capacity (FVC)

Vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · liters
Change From Baseline in Post-bronchodilator Forced Vital Capacity (FVC)
litersRoflumilastPlacebo
Change From Baseline in Post-bronchodilator Forced Vital Capacity (FVC)0.094 ± 0.017-0.007 ± 0.016
SecondaryChange From Baseline in Pre-bronchodilator Forced Expiratory Flow 25-75%

Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · liters/second
Change From Baseline in Pre-bronchodilator Forced Expiratory Flow 25-75%
liters/secondRoflumilastPlacebo
Change From Baseline in Pre-bronchodilator Forced Expiratory Flow 25-75%0.023 ± 0.005-0.010 ± 0.005
SecondaryChange From Baseline in Post-bronchodilator Forced Expiratory Flow 25-75%

Forced expiratory flow 25-75% (FEF25-75%) is the flow (or speed) of air coming out of the lung during the middle half of a forced expiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · liters/second
Change From Baseline in Post-bronchodilator Forced Expiratory Flow 25-75%
liters/secondRoflumilastPlacebo
Change From Baseline in Post-bronchodilator Forced Expiratory Flow 25-75%0.022 ± 0.005-0.008 ± 0.005
SecondaryChange From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3)

FEV3 is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of pre-bronchodilator FEV3, time and a treatment-by-time interaction as independent variables.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · liters
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3)
litersRoflumilastPlacebo
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3)0.072 ± 0.012-0.030 ± 0.012
SecondaryChange From Baseline in Post-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3)

FEV3 is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of post-bronchodilator FEV3, time and a treatment-by-time interaction as independent variables.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · liters
Change From Baseline in Post-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3)
litersRoflumilastPlacebo
Change From Baseline in Post-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3)0.064 ± 0.012-0.030 ± 0.011
SecondaryChange From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6)

FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first six seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of pre-bronchodilator FEV6, time and a treatment-by-time interaction as independent variables.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · liters
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6)
litersRoflumilastPlacebo
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6)0.084 ± 0.014-0.031 ± 0.014
SecondaryChange From Baseline in Post-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6)

FEV6 is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value of post-bronchodilator FEV6, time and a treatment-by-time interaction as independent variables.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · liters
Change From Baseline in Post-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6)
litersRoflumilastPlacebo
Change From Baseline in Post-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6)0.078 ± 0.013-0.032 ± 0.013
SecondaryChange From Baseline in Pre-bronchodilator Peak Expiratory Flow Rate (PEF)

PEF is the maximal flow (or speed) achieved during the maximally forced expiration initiated at full inspiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · liters/minute
Change From Baseline in Pre-bronchodilator Peak Expiratory Flow Rate (PEF)
liters/minuteRoflumilastPlacebo
Change From Baseline in Pre-bronchodilator Peak Expiratory Flow Rate (PEF)0.096 ± 0.027-0.036 ± 0.026
SecondaryChange From Baseline in Post-bronchodilator Peak Expiratory Flow Rate (PEF)

PEF is the maximal flow (or speed) achieved during the maximally forced expiration initiated at full inspiration. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol. Change from baseline over 24 weeks of treatment was calculated from a repeated measures analysis of covariance (ANCOVA) model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · liters/minute
Change From Baseline in Post-bronchodilator Peak Expiratory Flow Rate (PEF)
liters/minuteRoflumilastPlacebo
Change From Baseline in Post-bronchodilator Peak Expiratory Flow Rate (PEF)0.099 ± 0.027-0.030 ± 0.027
SecondaryChange From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity

The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication.

Time frame:
Baseline and Week 24
Reported as:
Median · percent FEV1/FVC
Change From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity
percent FEV1/FVCRoflumilastPlacebo
Change From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity-0.570 ± 4.5667-1.370 ± 4.9968
SecondaryChange From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity

The FEV1/FVC ratio represents the percentage of vital capacity expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol.

Time frame:
Baseline and Week 24
Reported as:
Median · percent FEV1/FVC
Change From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity
percent FEV1/FVCRoflumilastPlacebo
Change From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity-0.320 ± 4.5400-0.940 ± 5.1677
SecondaryChange From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds

The FEV1/FEV6 ratio represents the percentage of the volume of air expired in the first six seconds that is expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication.

Time frame:
Baseline and Week 24
Reported as:
Median · percentage of FEV1/FEV6
Change From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds
percentage of FEV1/FEV6RoflumilastPlacebo
Change From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds-0.210 ± 3.9213-0.950 ± 3.9173
SecondaryChange From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds

The FEV1/FEV6 ratio represents the percentage of the volume of air expired in the first six seconds that is expelled from the lungs during the first second of a forced exhalation. Pulmonary function testing was performed using centralized spirometry prior to taking study medication. Post-bronchodilator measurements were taken 30 minutes after four inhalations of 100 μg salbutamol.

Time frame:
Baseline and Week 24
Reported as:
Mean · percentage of FEV1/FEV6
Change From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds
percentage of FEV1/FEV6RoflumilastPlacebo
Change From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds-0.340 ± 3.7240-0.420 ± 4.1957
SecondaryChange From Baseline in COPD Symptom Scores

Symptoms of chronic bronchitis with respect to cough and sputum production were assessed daily by the patient and recorded in a diary. Symptoms were assessed on a 4-point scale as follows: Cough: 0: no cough; 1: mild cough (at some time during the day); 2: moderate cough (regularly during the day); 3: severe cough (never free of cough or feeling free of need to cough). Sputum production: 0: no sputum production (unnoticeable); 1: mild sputum production (noticeable as a problem); 2: moderate sputum production (frequent inconvenience); 3: severe sputum production (constant problem). Change from Baseline is reported for cough and sputum separately, and for the sum of the 2 scores (range 0 - 6). Least squares means (LSM) are from a repeated measures ANCOVA model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in COPD Symptom Scores
units on a scaleRoflumilastPlacebo
Score Sum (n=282, 296)0.013 ± 0.0540.064 ± 0.053
Cough (n=284, 299)-0.019 ± 0.0290.036 ± 0.028
Sputum (n=284, 296)0.035 ± 0.0300.037 ± 0.029
SecondaryChange From Baseline in Use of Rescue Medication

Salbutamol (given by metered dose inhaler and spacer) was used as rescue medication according to the individual needs of a patient. Each use was documented in the patient's paper diary. Least squares means (LSM) are from a repeated measures ANCOVA model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · puffs/day
Change From Baseline in Use of Rescue Medication
puffs/dayRoflumilastPlacebo
Change From Baseline in Use of Rescue Medication-0.485 ± 0.134-0.518 ± 0.131
SecondaryTransition Dyspnoea Index (TDI) Total Score at Week 24

The TDI is a recognized questionnaire to measure dyspnoea (shortness of breath) in patients with COPD. Questions from the TDI were used to assess the 3 components: "change in functional impairment", "change in magnitude of task" and "change in magnitude of effort". Transitions or changes from baseline are rated from -3 (major deterioration) to +3 (major improvement), and summed to give a total score ranging from -9 to +9. Least squares means (LSM) are from a repeated measures ANCOVA model with treatment, baseline value, time and a treatment-by-time interaction as independent variables.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · units on a scale
Transition Dyspnoea Index (TDI) Total Score at Week 24
units on a scaleRoflumilastPlacebo
Transition Dyspnoea Index (TDI) Total Score at Week 241.335 ± 0.1241.396 ± 0.122
SecondaryPercentage of Participants With Moderate or Severe COPD Exacerbations

A COPD exacerbation is an event characterised by a worsening in the patient's baseline dyspnoea, or cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management, and may be accompanied by increased wheeze, chest tightness, purulent sputum and symptoms of cold and/or fatigue. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

Time frame:
24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Moderate or Severe COPD Exacerbations
percentage of participantsRoflumilastPlacebo
No exacerbations81.884.7
One exacerbation15.012.8
Two exacerbations2.61.9
Three exacerbations0.60.6
SecondaryMean Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year

The mean rate of COPD exacerbations per patient per year rate = (number of exacerbations per treatment group/time to study withdrawal per treatment group) \* 365. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

Time frame:
24 weeks
Reported as:
Number · exacerbations per patient per year
Mean Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year
exacerbations per patient per yearRoflumilastPlacebo
Mean Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year0.550.44
SecondaryTime to Onset of First Moderate or Severe COPD Exacerbation

Time to onset of a COPD exacerbation is defined as onset date of COPD exacerbation - date of first intake of study drug + 1 day. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

Time frame:
24 weeks
Reported as:
Median · days
Time to Onset of First Moderate or Severe COPD Exacerbation
daysRoflumilastPlacebo
Time to Onset of First Moderate or Severe COPD Exacerbation67.0 (3 to 165)86.0 (2 to 168)
SecondaryTime to Onset of Second Moderate or Severe COPD Exacerbation

Time to onset of a COPD exacerbation is defined as onset date of COPD exacerbation - date of first intake of study drug + 1 day. At least 10 days between the stop date of an exacerbation and the start date of the following exacerbation was required for these to be be considered as two separate COPD exacerbations. COPD exacerbations were categorized as follows: - Severe: Requiring hospitalization and/or leading to death; - Moderate: Requiring oral or parenteral glucocorticosteroid therapy.

Time frame:
24 weeks
Reported as:
Median · days
Time to Onset of Second Moderate or Severe COPD Exacerbation
daysRoflumilastPlacebo
Time to Onset of Second Moderate or Severe COPD Exacerbation119.5 (50 to 166)117.0 (71 to 163)
SecondaryNumber of Participants With Adverse Events

An adverse event (AE) is any untoward medical occurrence in a clinical trial participant regardless of causal relationship to study drug and regardless whether study drug has been administered. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A non-serious AE is any AE that does not meet the criteria above. Each AE was assessed by the Investigator as either 'related' or 'not related' to study drug.

Time frame:
24 weeks
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsRoflumilastPlacebo
All AEs213196
Non-serious AEs189172
Serious AEs (including death)6248
Death22
Serious AEs not including death6046
AEs with suggested relationship to trial treatment6518
AEs leading to withdrawal from the trial152
AEs not recovered at trial termination5445
AEs with changes in concomitant medication164155

Adverse events

Collected over 24 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roflumilast—62/315 (19.7%)143/315 (45.4%)
Placebo—48/311 (15.4%)133/311 (42.8%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventRoflumilastPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders44/31539/311
Colonic polypGastrointestinal disorders1/3152/311
PneumoniaInfections and infestations2/3152/311
Acute myocardial infarctionCardiac disorders2/3150/311
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/3150/311
Benign prostatic hyperplasiaReproductive system and breast disorders2/3151/311
Angina unstableCardiac disorders1/3151/311
Cardiac failureCardiac disorders1/3151/311
HydroceleCongenital, familial and genetic disorders0/3151/311
AppendicitisInfections and infestations1/3151/311
Most frequent other events
Most frequent other events
EventRoflumilastPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders90/31589/311
NasopharyngitisInfections and infestations28/31545/311
DiarrhoeaGastrointestinal disorders21/3153/311
Decreased appetiteMetabolism and nutrition disorders19/3152/311
Upper respiratory tract infectionInfections and infestations17/31518/311

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RoflumilastPlaceboTotal
Mean64.2 ± 8.7664.0 ± 8.2764.1 ± 8.51
Gender
Gender(Participants)RoflumilastPlaceboTotal
Female302757
Male283286569
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RoflumilastPlaceboTotal
American Indian or Alaska Native000
Asian313313626
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Height
Height(cm)RoflumilastPlaceboTotal
Mean166.2 ± 7.27165.9 ± 7.12166.1 ± 7.20
Weight
Weight(kg)RoflumilastPlaceboTotal
Mean60.4 ± 11.0061.8 ± 10.5461.1 ± 10.78
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)RoflumilastPlaceboTotal
Mean21.8 ± 3.4222.4 ± 3.4322.1 ± 3.44
Chronic obstructive pulmonary disease (COPD) severity
Chronic obstructive pulmonary disease (COPD) severity(Participants)RoflumilastPlaceboTotal
Mild112
Moderate281644
Severe196204400
Very severe8892180
COPD disease characteristics
COPD disease characteristics(Participants)RoflumilastPlaceboTotal
Predominantly chronic bronchitis5661117
Combined emphysema and chronic bronchitis217216433
Predominantly emphysema403676

9 further baseline measures are reported on the registry.

08

Study locations

15 sites
  • Beijing, China
  • Changsha, China
  • Chengdu, China
  • Chongqing, China
  • Fuzhou, China
  • Guangzhou, China
  • Hangzhou, China
  • Nanjing, China
  • Nanning, China
  • Qingdao, China
  • Shanghai, China
  • Shenyang, China
  • Shijiazhuang, China
  • Hong Kong, Hong Kong
  • Singapore, Singapore
09

References and documents

Publications

  • Zheng J, Yang J, Zhou X, Zhao L, Hui F, Wang H, Bai C, Chen P, Li H, Kang J, Brose M, Richard F, Goehring UM, Zhong N. Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study. Chest. 2014 Jan;145(1):44-52. doi: 10.1378/chest.13-1252. PubMed 24135893 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2011
First posted
Mar 11, 2011
Start
Mar 2011
Primary completionActual
May 2012
CompletionActual
May 2012
Results first posted
Aug 2, 2013
Last update
Feb 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01313494
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 11, 2011
Start date
Mar 2011
Primary completion
May 2012
Completion
May 2012
Results posted
Aug 2, 2013
Last update
Feb 1, 2017

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion